Study of three drugs vs standard care for HER2-high stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Your cancer must have high levels of HER2 (a protein that helps cancer grow).
- You must not have received any previous cancer treatment for advanced or metastatic disease, or if you had treatment before surgery, it must have been at least 6 months ago since it stopped working.
- You must be in good general health, able to care for yourself (ECOG score 0 or 1), and expected to live more than 12 weeks.
- You must have at least one tumor that can be measured on scans.
- You must have adequate organ function and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three drugs (disitamab vedotin, tislelizumab, and chemotherapy) compared to two of them (tislelizumab plus chemotherapy) for people with advanced stomach or gastroesophageal junction cancer that has low levels of a protein called HER2. It aims to see if adding the third drug helps shrink or control the cancer better.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests a new combination of two drugs for stomach cancer that has spread and shows a specific protein (HER2). The goal is to see if the combination helps patients who haven't had treatment for advanced disease.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
Hear when a new Gastric Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.